Kais Aldabbagh
Overview
Explore the profile of Kais Aldabbagh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
97
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oudard S, Tran Y, Helissey C, Vauchier C, Ratta R, Bennamoun M, et al.
Eur Urol Oncol
. 2024 Aug;
8(1):126-134.
PMID: 39143002
Background And Objective: The CABASTY study showed that more frequent administration of a lower dose of cabazitaxel (CBZ) reduced toxicity in older men with metastatic castration-resistant prostate cancer (mCRPC), without...
2.
Oudard S, Ratta R, Voog E, Barthelemy P, Thiery-Vuillemin A, Bennamoun M, et al.
JAMA Oncol
. 2023 Oct;
9(12):1629-1638.
PMID: 37883073
Importance: Many patients 65 years or older with metastatic castration-resistant prostate cancer (mCRPC) are denied taxane chemotherapy because this treatment is considered unsuitable. Objective: To determine whether biweekly cabazitaxel (CBZ),...
3.
Lievre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, et al.
Eur J Cancer
. 2020 Oct;
141:62-81.
PMID: 33129039
Background: Cancer patients are thought to have an increased risk of developing severe Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, predictive factors for...
4.
Aldabbagh K, Pouderoux S, Roca L, Poujol S, Fabbro M, Romieu G, et al.
Breast Cancer
. 2010 Nov;
19(1):16-22.
PMID: 21088942
Background: Since 2004, metastatic breast cancer patients pretreated with anthracyclines, taxanes, and capecitabine have been treated in our institution with a combination of mitomycin C, methotrexate, and VP-16 (VMM). We...